Cargando…
Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy
Background: Treatment of breast cancer (BC) includes locoregional and systemic therapies depending on tumor and patient’s characteristics. Inositol hexaphosphate (IP6) is known as a strong antioxidant agent, able to improve local (i.e., breast region) side effects, functional status and quality-of-l...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400775/ https://www.ncbi.nlm.nih.gov/pubmed/34442400 http://dx.doi.org/10.3390/jpm11080756 |
_version_ | 1783745394631507968 |
---|---|
author | Amabile, Maria Ida De Luca, Alessandro Tripodi, Domenico D’Alberti, Elena Melcarne, Rossella Imbimbo, Giovanni Picconi, Orietta D’Andrea, Vito Vergine, Massimo Sorrenti, Salvatore Molfino, Alessio |
author_facet | Amabile, Maria Ida De Luca, Alessandro Tripodi, Domenico D’Alberti, Elena Melcarne, Rossella Imbimbo, Giovanni Picconi, Orietta D’Andrea, Vito Vergine, Massimo Sorrenti, Salvatore Molfino, Alessio |
author_sort | Amabile, Maria Ida |
collection | PubMed |
description | Background: Treatment of breast cancer (BC) includes locoregional and systemic therapies depending on tumor and patient’s characteristics. Inositol hexaphosphate (IP6) is known as a strong antioxidant agent, able to improve local (i.e., breast region) side effects, functional status and quality-of-life. We investigated some potential beneficial effects, including hematological and local, of the combined therapy with oral myo-inositol administration and topical IP6 application in patients undergoing surgery for BC and eligible to adjuvant chemotherapy. Methods: We considered BC patients randomly assigned to the Inositol Group (oral myo-inositol + IP6 local application for the entire neoadjuvant treatment period) and to the Control Group (standard of care). The EORTC QLQ-BR23 and QLQ-C30 questionnaires were administered to both groups and blood parameters were assessed as per clinical routine practice at baseline (before starting adjuvant chemotherapy), T1 (after the first two doses of epirubicin-cyclophosphamide regimen), T2 (at the end of epirubicin-cyclophosphamide regimen), T3 (after the first six doses of paclitaxel regimen), and T4 (at the end of the paclitaxel treatment). Results: A total of 36 BC patients were considered, 18 in the Inositol Group and 18 in the Control Group. The Inositol Group showed a lower decrease in red blood cells, hemoglobin levels and white blood cells with respect to controls (p ≤ 0.02), as well as amelioration in scores related to breast and arm local symptoms (p ≤ 0.02), body image (p = 0.04) and quality-of-life related symptoms (p ≤ 0.04). Conclusions: In our cohort of BC patients, a combined treatment with oral myo-inositol + IP6 local application was able to improve local symptoms and quality-of-life related symptoms which represent clinically relevant aspects associated with patient’s prognosis. |
format | Online Article Text |
id | pubmed-8400775 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84007752021-08-29 Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy Amabile, Maria Ida De Luca, Alessandro Tripodi, Domenico D’Alberti, Elena Melcarne, Rossella Imbimbo, Giovanni Picconi, Orietta D’Andrea, Vito Vergine, Massimo Sorrenti, Salvatore Molfino, Alessio J Pers Med Article Background: Treatment of breast cancer (BC) includes locoregional and systemic therapies depending on tumor and patient’s characteristics. Inositol hexaphosphate (IP6) is known as a strong antioxidant agent, able to improve local (i.e., breast region) side effects, functional status and quality-of-life. We investigated some potential beneficial effects, including hematological and local, of the combined therapy with oral myo-inositol administration and topical IP6 application in patients undergoing surgery for BC and eligible to adjuvant chemotherapy. Methods: We considered BC patients randomly assigned to the Inositol Group (oral myo-inositol + IP6 local application for the entire neoadjuvant treatment period) and to the Control Group (standard of care). The EORTC QLQ-BR23 and QLQ-C30 questionnaires were administered to both groups and blood parameters were assessed as per clinical routine practice at baseline (before starting adjuvant chemotherapy), T1 (after the first two doses of epirubicin-cyclophosphamide regimen), T2 (at the end of epirubicin-cyclophosphamide regimen), T3 (after the first six doses of paclitaxel regimen), and T4 (at the end of the paclitaxel treatment). Results: A total of 36 BC patients were considered, 18 in the Inositol Group and 18 in the Control Group. The Inositol Group showed a lower decrease in red blood cells, hemoglobin levels and white blood cells with respect to controls (p ≤ 0.02), as well as amelioration in scores related to breast and arm local symptoms (p ≤ 0.02), body image (p = 0.04) and quality-of-life related symptoms (p ≤ 0.04). Conclusions: In our cohort of BC patients, a combined treatment with oral myo-inositol + IP6 local application was able to improve local symptoms and quality-of-life related symptoms which represent clinically relevant aspects associated with patient’s prognosis. MDPI 2021-07-30 /pmc/articles/PMC8400775/ /pubmed/34442400 http://dx.doi.org/10.3390/jpm11080756 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Amabile, Maria Ida De Luca, Alessandro Tripodi, Domenico D’Alberti, Elena Melcarne, Rossella Imbimbo, Giovanni Picconi, Orietta D’Andrea, Vito Vergine, Massimo Sorrenti, Salvatore Molfino, Alessio Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy |
title | Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy |
title_full | Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy |
title_fullStr | Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy |
title_full_unstemmed | Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy |
title_short | Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy |
title_sort | effects of inositol hexaphosphate and myo-inositol administration in breast cancer patients during adjuvant chemotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400775/ https://www.ncbi.nlm.nih.gov/pubmed/34442400 http://dx.doi.org/10.3390/jpm11080756 |
work_keys_str_mv | AT amabilemariaida effectsofinositolhexaphosphateandmyoinositoladministrationinbreastcancerpatientsduringadjuvantchemotherapy AT delucaalessandro effectsofinositolhexaphosphateandmyoinositoladministrationinbreastcancerpatientsduringadjuvantchemotherapy AT tripodidomenico effectsofinositolhexaphosphateandmyoinositoladministrationinbreastcancerpatientsduringadjuvantchemotherapy AT dalbertielena effectsofinositolhexaphosphateandmyoinositoladministrationinbreastcancerpatientsduringadjuvantchemotherapy AT melcarnerossella effectsofinositolhexaphosphateandmyoinositoladministrationinbreastcancerpatientsduringadjuvantchemotherapy AT imbimbogiovanni effectsofinositolhexaphosphateandmyoinositoladministrationinbreastcancerpatientsduringadjuvantchemotherapy AT picconiorietta effectsofinositolhexaphosphateandmyoinositoladministrationinbreastcancerpatientsduringadjuvantchemotherapy AT dandreavito effectsofinositolhexaphosphateandmyoinositoladministrationinbreastcancerpatientsduringadjuvantchemotherapy AT verginemassimo effectsofinositolhexaphosphateandmyoinositoladministrationinbreastcancerpatientsduringadjuvantchemotherapy AT sorrentisalvatore effectsofinositolhexaphosphateandmyoinositoladministrationinbreastcancerpatientsduringadjuvantchemotherapy AT molfinoalessio effectsofinositolhexaphosphateandmyoinositoladministrationinbreastcancerpatientsduringadjuvantchemotherapy |